



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/954,679	09/12/2001	Donna T. Ward	RTS-0212	7534

7590 11/17/2004

Jane Massey Licata
Licata & Tyrrell, P.C.
66 East Main Street
Marlton, NJ 08053

EXAMINER

LACOURCIERE, KAREN A

ART UNIT	PAPER NUMBER
	1635

DATE MAILED: 11/17/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

09/954,679	WARD ET AL.
Examiner	Art Unit
Karen A. Lacourciere	1635

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM
THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(e). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 04 September 2003.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1,2 and 4-23 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1,2 and 4-23 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. §§ 119 and 120

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.
- 13) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.
a) The translation of the foreign language provisional application has been received.
- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

Attachment(s)

- Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s). _____
- Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) Notice of Informal Patent Application (PTO-152)
- Information Disclosure Statement(s) (PTO-1449) Paper No(s) 8-18-03 6) Other: _____

DETAILED ACTION

Claim Rejections - 35 USC § 112

The rejection of record of claim 18 under 35 U.S.C. 112, second paragraph, is withdrawn in response to Applicant's amendments filed September 4, 2003.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 15-20 are maintained as rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a method of inhibiting the expression of ribonuclease L in cells and tissues in vitro (cell culture) using antisense targeted to a nucleic acid encoding ribonuclease L (SEQ ID NO:3), does not reasonably provide enablement for a method of inhibiting the expression of ribonuclease L in cells or tissues in vivo (whole organism), a method of treatment or a method of modulating RNA interference using an antisense targeted to a nucleic acid encoding ribonuclease L. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.

The following factors have been considered in formulating this rejection (*In re Wands*, 858F.2d 731, 8 USPQ2d 1400 (Fed. Cir. 1988)): the breadth of the claims, the nature of the invention, the state of the prior art, the relative skill of those in the art, the predictability or unpredictability of the art, the amount of direction or guidance

presented, the presence or absence of working examples of the invention and the quantity of experimentation necessary.

Claims 15-20 are drawn broadly to inhibition of the expression of ribonuclease L in any cell *in vivo* (whole organism) for the treatment of any disease that is associated with ribonuclease L, including treating any disease or condition resulting from an infection, any disease or condition associated with ribonuclease L that is the result of aberrant apoptosis, or any cancer using antisense targeted to a nucleic acid encoding ribonuclease L.

The specification provides examples wherein chimeric phosphorothioate antisense targeted to a nucleic acid encoding ribonuclease L inhibited the expression ribonuclease L *in vitro* (cell culture) in human cell lines. The specification does not demonstrate any correlation with the inhibition of ribonuclease L in cell culture and a treatment effect for any disease or condition associated with ribonuclease L. The specification does not present any examples wherein antisense targeted to ribonuclease L was delivered to cells *in vivo* (whole organism), nor wherein antisense targeted to ribonuclease L inhibited the expression of ribonuclease L in cells *in vivo* (whole organism). The specification does not provide any examples wherein treatment effects were obtained for any disease or condition, including an infection or a disease or condition resulting from aberrant apoptosis or cancer using antisense targeted to ribonuclease L. The specification does not demonstrate modulating the expression of ribonuclease L using antisense, only inhibiting of ribonuclease L. The specification does not demonstrate modulating RNA interference using antisense targeted to

ribonuclease L, or inhibiting or increasing RNA interference using antisense to ribonuclease L. The specification does not demonstrate that ribonuclease L is associated with RNA interference, nor does the art recognize its involvement.

The specification does not present any guidance on what specific diseases or conditions can be treated using antisense targeted to ribonuclease L including specific infection, cancers or conditions which arise from aberrant apoptosis, and what cells to target for a particular disease or condition.

At the time the instant invention was made, the therapeutic use of antisense oligonucleotides was a highly unpredictable art due to obstacles that continue to hinder the therapeutic application of antisense *in vivo* (whole organism) (see for example Agrawal et al. (Molecular Medicine Today, Vol 6, p 72-81, February 2000), Branch (TIBS 23, Feb 1998, p45-50), Green et al. (J. Am Coll. Surg., Vol 191, No. 1, July 2000, p 93-105), Jen et al. (Stem Cells 2000, Vol. 18, p 307-319)). Such obstacles include, for example, problems with delivery, target accessibility and the potential for unpredictable nonantisense effects. Jen et al. state (see page 313, second column, second paragraph) "One of the major limitations for the therapeutic use of AS-ODNs and ribozymes is the problem of delivery....Presently, some success has been achieved in tissue culture, but efficient delivery for *in vivo* animal studies remains questionable". Jen et al. outlines many of the factors limiting the application of antisense for therapeutic purposes and concludes (see p 315, second column), "Given the state of the art, it is perhaps not surprising that effective and efficient clinical translation of the antisense strategy has proven elusive."

Green et al. state, "It is clear that the evolution of antisense technology from a laboratory research tool into a mechanism for designing active and effective drugs is far from complete. Although there is little doubt that systemically administered antisense ODNs can inhibit the expression of specific genes in patients, the effectiveness of such therapy in modifying the course of a particular illness has not yet been established....Clearly, additional work must be done to unravel the complex problems associated with drug delivery, mRNA targeting and aptameric, nonantisense effects."

Given this unpredictability, the skilled artisan would require specific guidance to practice the claimed methods *in vivo*, with a resultant therapeutic outcome, as claimed. The specification provides examples wherein antisense is delivered to cells *in vitro* and the expression of ribonuclease L is inhibited, however, cell culture examples are generally not predictive of *in vivo* inhibition due to differences in metabolites and clearance rates, local concentration of antisense, differences in target site accessibility, cellular uptake differences and the potential for non-antisense side effects. Often formulations and techniques for delivery *in vitro* (cell culture) are not applicable *in vivo* (whole organism) (see for example Jen et al., page 313, second column, second paragraph). For example, Agrawal et al. (see p 79-80, section entitled *Cellular uptake facilitators for in vitro studies*) states "The cellular uptake of negatively charged oligonucleotides is one of the important factors in determining the efficacy of antisense oligonucleotides.....In vitro, cellular uptake of antisense oligonucleotides depends on many factors, including cell type, kinetics of uptake, tissue culture conditions, and chemical nature, length and sequence of the oligonucleotide. Any one of these factors

can influence the biological activity of an antisense oligonucleotide." Due to differences in the physiological conditions of a cell *in vitro* versus *in vivo*, the uptake and biological activity observed *in vitro* would not predictably translate to *in vivo* results.

The field of antisense, to date, does not provide guidelines by which antisense can be routinely delivered to generally any cell type *in vivo* (whole organism) at a concentration effective to result in a predictable therapeutic effect. The specification does not provide specific guidance by which one skilled in the art would expect to be able to deliver antisense targeted to ribonuclease L to generally any target cell or tissue *in vivo* (whole organism) at a concentration effective to provide a pharmaceutical effect or to treat the broad range of diseases encompassed by the claims or to modulate RNA interference, particularly wherein the claims specify a pharmaceutically effective amount.

In order to practice the invention claimed, over the full scope claimed, one skilled in the art would need to undergo undue trial and error experimentation, beyond the teachings of the instant specification. The quantity of undue experimentation would include the determination of what specific diseases and conditions can be treated by the inhibition of the expression of ribonuclease L, what specific cells to target with ribonuclease L antisense for the treatment of a particular disease or condition, and how to specifically deliver antisense to a target cell *in vivo* (whole organism) at a concentration effective to result in inhibition of the expression of ribonuclease L to a level sufficient to result in a pharmaceutical effect or to treat a disease. The skilled artisan would need to determine if RNA interference can be modulated using

ribonuclease L antisense and is unlikely to be able to do so, given that each antisense disclosed in the specification inhibits ribonuclease L and it is unclear that ribonuclease L is even associated with the RNA interference pathway. Additionally, this undue experimentation would include the determination of such factors as dosage, route of administration, disposition of the antisense molecule in tissues, and the half life and stability of the antisense molecule *in vivo*. Given the art recognized unpredictability of the therapeutic application of antisense *in vivo* (whole organism), this determination would not be routine and would require undue trial and error experimentation.

Therefore, due to the broad scope of the methods of treatment claimed and the *in vivo* modulation claimed, the state of the art of antisense, the level of unpredictability of *in vivo* (whole organism) methods of treatment using antisense, the lack of specific guidance for the *in vivo* (whole organism) application of antisense methods of treatment and the lack of working examples or examples which correlate with the claimed methods, one skilled in the art would not be able to practice the methods of claims 15-20 over the full scope claimed without undue trial and error experimentation.

Claims 22 and 23 are rejected under 35 USC 112 first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection.

Claims 22 and 23 add the new limitations wherein the claimed antisense compounds inhibit the expression of ribonuclease L at least 80% or more and at least 90% or more. Applicant points to Table 1 and the accompanying text to support these newly added limitations, however, support could not be found for these limitations in Table 1, nor could support be found anywhere else in the originally filed specification or claims and, therefore, these limitations are considered to be new matter.

Response to Arguments

Applicant's arguments filed September 4, 2003 have been fully considered but they are not persuasive. In response to the rejection of record of claims 15-20 under 35 USC, first paragraph, as not fully enabled by the specification, Applicant argues that the claimed methods are fully enabled.

Applicant argues that the crux of the rejection appears to be that the specification has correlated in vitro results with in vivo claims, especially when the specification has not provided any working examples. Applicant argues that working examples are not required. These arguments are not persuasive because the rejection of record is not based solely on the lack of working examples, but on an evaluation of all of the Wands factors, one of which is the presence or absence of working examples. Working examples for in vivo methods are not present in the instant specification and, therefore, this is one criteria not met in the Wands factors. When evaluated with all of the Wands factors and the state of the art, which indicates the importance of working examples in the field of in vivo antisense inhibition, the scope of the claimed methods directed to in

vivo methods is not enabled by the specification. The claims have not been held to the standards of the FDA, as alleged in Applicant's arguments.

Applicant argues that the rejection of record has not considered the numerous art references that support the enablement of the claimed methods prior to the date of filing for the instant application. Applicant individually argues each of the prior art references used in the rejection of record to support the unpredictability of the filed of antisense. Applicant argues that the reference Jen et al. does not indicate that antisense is wholly unpredictable and doomed to failure, but rather reports potential problems with finding a clinically effective antisense drug. This is not persuasive because the claimed methods encompass clinically effective methods and require a treatment effect, which is the aspect of antisense methods Jen et al. is saying is unpredictable, and Applicant appears to agree that Jen et al. is stating. Read as a whole, Jen et al. supports the unpredictability of antisense in vivo, particularly for methods of treatment using antisense in vivo, as instantly claimed.

Applicant argues that Green et al. reference, taken as a whole, supports that the concept of antisense technology is predictable and functional both in vitro and in vivo. This argument is not persuasive. Applicant selectively points to passages in Green et al. that are positive about advances within the filed of antisense and specific examples within the antisense field where in vivo, unexpected results have been obtained, however, as a whole Green et al. recognizes that the filed is not predictable. For example, Green et al. concludes Green et al. state, "It is clear that the evolution of antisense technology from a laboratory research tool into a mechanism for designing

active and effective drugs is far from complete. Although there is little doubt that systemically administered antisense ODNs can inhibit the expression of specific genes in patients, the effectiveness of such therapy in modifying the course of a particular illness has not yet been established....Clearly, additional work must be done to unravel the complex problems associated with drug delivery, mRNA targeting and aptameric, nonantisense effects." Despite the recent advances in the field, Green supports that *in vivo* antisense applications were not predictable.

Applicant argues that Agrawal et al. reviews factors involved in antisense chemistry delivery and design, but does not say that these factors are insurmountable or unpredictable and demonstrates that there are successful *in vitro* and *in vivo* examples for antisense. These arguments have not been found to be persuasive because the citation reference in the rejection of record within Agrawal et al. directed to cellular uptake supports that uptake of an antisense molecule in a cell *in vitro* does not correlate well with uptake of a cell *in vivo* and does not generally correlate for different types of antisense molecules and different cell types. This helps to support the conclusion that the examples provided in the specification would not be expected to correlate with the scope of the methods claimed.

Applicant argues that the Branch reference supports that the skilled artisan sees promise in the use of antisense and that although there may be experimentation required it is not undue. This is not found to be persuasive. Read as a whole, Branch clearly indicates that antisense is unpredictable to apply *in vivo*, for example, due to unpredictable, non antisense effects.

Applicant argues that the specification provides a reasonable amount of guidance with respect to the direction in which the experimentation should proceed and outlines the types of compounds that can be used and method used to inhibit the expression of ribonuclease L in cells and tissues. These arguments are not persuasive. The guidance provided in the specification is broad general guidance and does not provide the specific guidance that would be required to practice the claimed methods *in vivo*. The compounds and formulations and delivery methods listed in the specification are general and provide a laundry list of almost every type of known antisense modification and delivery formulation known in the art, without any specific guidance for the skilled artisan as to how to actually apply these varied formulations, modifications and delivery methods to achieve a particular outcome, for example, what particular formulations and specific combination of modifications would be effective to delivery a particular ribonuclease L antisense to a target cell *in vivo*, what particular cell type to target for a specific disease or condition, and how to actually achieve inhibition of ribonuclease L in a cell *in vivo* in a way that would result in a treatment effect for a specific disease or condition.

Applicant argues that the prior art demonstrates that *in vitro* results correlate with *in vivo* results and cites five references wherein an antisense *in vitro* model provided results that correlate with an *in vivo* result. This is not found to be persuasive because although there are examples in the prior art wherein antisense has been used successfully *in vivo*, and wherein *in vitro* results correlate with *in vivo* results, this correlation is unpredictable and does not universally apply to antisense. Applicant has

not shown how the results demonstrated in these references would be expected to correlate with the broad scope of their claimed methods, for example, whether any of the cited references target the same cell types as would be required for a treatment method for a disorder or condition associated with ribonuclease L overexpression. Further, each of these references is directed to individual examples of unexpected success with single antisense molecules and do not suggest that the field of antisense as a whole has become predictable. The references cited in the rejection of record examine the field of antisense broadly and describe the state of the art as a whole and conclude that *in vivo*, therapeutic applications of antisense technology, as required in the claimed treatment methods, is unpredictable. In evaluating the Wands factors for the claimed methods and based on the teachings of the instant specification due to the broad scope of the methods of treatment claimed and the *in vivo* modulation claimed, the state of the art of antisense, the level of unpredictability of *in vivo* (whole organism) methods of treatment using antisense, the lack of specific guidance for the *in vivo* (whole organism) application of antisense methods of treatment and the lack of working examples or examples which correlate with the claimed methods, one skilled in the art would not be able to practice the methods of claims 15-20 over the full scope claimed without undue trial and error experimentation.

Claim Rejections - 35 USC § 102 or 35 USC § 103

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

Art Unit: 1635

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1, 2 and 11 are maintained as rejected and new claims 21-23 are rejected under 35 U.S.C. 102(b) or 35 USC 103(a) as being anticipated by or obvious over Ogawa et al. (WO 96/38034).

Ogawa et al. (WO 96/38034) disclose a 35-mer oligonucleotide that is fully complementary to SEQ ID NO:3 (see page 22, second sequence listed for RNaseL). Ogawa et al. was not available in English at the time this Office action was prepared, however, the claims have only been rejected on the basis of sequence information. The oligonucleotide disclosed by Ogawa et al. meets all of the structural requirements of the instant claims, the oligonucleotides would also be expected to specifically hybridize to nucleic acid encoding ribonuclease L, as per applicant's definition set forth in the specification as filed, page 10, lines 6-10.

Furthermore, since the prior art oligonucleotides meet all the structural limitations of the claims, the prior art oligonucleotides would then be considered to "inhibit expression" of the gene as claimed, absent evidence to the contrary. See, for example, MPEP § 2112, which states "[w]here applicant claims a composition in terms

of a function, property or characteristic and the composition of the prior art is the same as that of the claim but the function is not explicitly disclosed by the reference, the examiner may make a rejection under both 35 U.S.C. 102 and 103, expressed as a 102/103 rejection. 'There is nothing inconsistent in concurrent rejections for obviousness under 35 U.S.C. 103 and for anticipation under 35 U.S.C. 102.' In re Best, 562 F.2d 1252, 1255 n.4, 195 USPQ 430, 433 n.4 (CCPA 1977). This same rationale should also apply to product, apparatus, and process claims claimed in terms of function, property or characteristic. Therefore, a 35 U.S.C. 102/103 rejection is appropriate for these types of claims as well as for composition claims."

Therefore, the instant invention is anticipated or obvious over Ogawa et al. (WO 96/38034).

Claims 1, 2, 11, 12 and 14 are maintained as rejected and new claims 21-23 are rejected under 35 U.S.C. 102(e) or 35 USC 103(a) as being anticipated by or obvious over Ogawa et al. (US 6,320,099).

Ogawa et al. (US 6,320,099) disclose a 35-mer oligonucleotide that is fully complementary to SEQ ID NO:3 (see SEQ ID NO 8, column 16, second primer for RNaseL). Ogawa et al. disclose their oligonucleotide in a composition comprising a pharmaceutically acceptable carrier (eg. water). The oligonucleotide disclosed by Ogawa et al. is disclosed as a primer, however, the oligonucleotide meets all of the structural requirements of the instant claims, the oligonucleotides would also be

expected to specifically hybridize to nucleic acid encoding ribonuclease L, as per applicant's definition set forth in the specification as filed, page 10, lines 6-10.

Furthermore, since the prior art oligonucleotides meet all the structural limitations of the claims, the prior art oligonucleotides would then be considered to "inhibit expression" of the gene as claimed, absent evidence to the contrary. See, for example, MPEP § 2112, which states "[w]here applicant claims a composition in terms of a function, property or characteristic and the composition of the prior art is the same as that of the claim but the function is not explicitly disclosed by the reference, the examiner may make a rejection under both 35 U.S.C. 102 and 103, expressed as a 102/103 rejection. 'There is nothing inconsistent in concurrent rejections for obviousness under 35 U.S.C. 103 and for anticipation under 35 U.S.C. 102.' In re Best, 562 F.2d 1252, 1255 n.4, 195 USPQ 430, 433 n.4 (CCPA 1977). This same rationale should also apply to product, apparatus, and process claims claimed in terms of function, property or characteristic. Therefore, a 35 U.S.C. 102/103 rejection is appropriate for these types of claims as well as for composition claims."

Therefore, the instant invention is anticipated or obvious over Ogawa et al. (US 6,320,099).

Response to Arguments

Applicant's arguments filed September 4, 2003 have been fully considered but they are not persuasive. In response to the rejection of record of claims 1, 2 and 11 under 35 U.S.C. 102(b) or 35 USC 103(a) as being anticipated by or obvious over

Ogawa et al. (WO 96/38034) and the rejection of claims 1, 2, 11, 12 and 14 under 35 U.S.C. 102(e) or 35 USC 103(a) as being anticipated by or obvious over Ogawa et al. (US 6,320,099), Applicant argues that there is no extrinsic or intrinsic evidence to support that the oligonucleotide disclosed in Ogawa et al. (WO 96/38034) or Ogawa et al. (US 6,320,099) can inhibit the expression of ribonuclease L. Applicant argues that the standard for inherency is that the alleged inherent characteristic must necessarily flow from the teachings of the applied prior art and that the Office has failed to provide a basis in fact and/or technical reasoning to support that the prior art oligonucleotides inhibit the expression of ribonuclease L, as required in the claims.

These arguments have not been found persuasive because the prior art oligonucleotides meet all of the structural limitations of the claimed oligonucleotides and therefore would be expected to have the same inhibitory characteristics, absent evidence to the contrary. The Office does not have the means to determine whether or not the prior art oligonucleotides inhibit the expression of ribonuclease L and Applicant has not provided any evidence to suggest that these oligonucleotides do not inhibit the expression of ribonuclease L. As the rejection applies to claim 11, there is no activity requirement in claim 11 and these arguments address a limitation not found in claim 11.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

Art Unit: 1635

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1, 2 and 4-15 are maintained as rejected and new claims 21-23 are under 35 U.S.C. 103(a) as being unpatentable over Maitra et al. (J. Virology Feb 1998, pages 1146-1152, reference AF on PTO form 1449, filed 09-12-2001) in view of Silverman et al. (US 6,028,243, reference AD on PTO form 1449, filed 09-12-2001), Zhou et al. (reference AL on PTO form 1449, filed 09-12-2001), Milner et al. and Barracchini et al.

Claims 1, 2, 4-15 and 21-23 are drawn to an antisense compound 8-50 nucleotides in length targeted to a nucleic acid encoding ribonuclease L (SEQ ID NO:3), wherein the antisense comprises modified bases, including 5-methylcytosine modifications, modified sugars, including 2'-O-methoxyethyl modifications, internucleoside linkage modifications, including phosphorothioate, chimeric antisense, and compositions comprising said antisense and a pharmaceutically acceptable carrier, including a colloidal dispersion system. The claims are further drawn to methods to

inhibit the expression of ribonuclease L in cells *in vitro* and wherein the claimed antisense compounds inhibit the expression of the target nucleic acid to varying degrees, ranging from 60%, 80%, 90% or more.

Maitra et al. teach antisense targeted to a nucleic acid encoding ribonuclease L expressed from a vector to inhibit the expression of ribonuclease L in cells *in vitro*. Maitra et al. do not teach antisense targeted to a nucleic acid encoding ribonuclease L of a length 8-50 nucleobases long. Maitra et al. do not teach antisense targeted to a nucleic acid encoding ribonuclease L wherein the antisense comprises a modified backbone, base or sugar, or chimeric antisense molecules.

Silverman et al. teach inhibiting the expression of ribonuclease L in cells using gene interruption to make a cell line useful to screen *in vitro* for antiviral drugs (see for example column 4).

Zhou et al. teach the full length sequence of a nucleic acid encoding ribonuclease L of SEQ ID NO:3.

Baracchini et al. teach 2'-O-methoxyethyl sugar modifications, 5-methyl cytosine base modifications, chimeric oligonucleotides and modified internucleoside linkages, including phosphorothioate linkages, to increase antisense stability and enhance affinity and antisense oligonucleotides of 8-30 nucleotides in length. Baracchini et al. further teach pharmaceutical carriers and colloidal dispersion systems (for example liposomes) for use in delivery of antisense compounds.

Milner et al. teach methods of screening for determining antisense targeted to any known gene.

It would have been obvious to one of ordinary skill in the art to make an antisense molecule targeted to ribonuclease L because Maitra et al. teach that antisense is a viable means to inhibit the expression of ribonuclease L in cells in vitro and Silverman et al. teach that a cell line comprising an inhibition of ribonuclease L was useful as a tool to screen for antiviral drugs, in vitro. It would have been obvious to one of ordinary skill in the art to make an antisense oligonucleotide targeted to a nucleic acid encoding ribonuclease L, as taught by Maitra et al., of a length within the range of 8-50 nucleobases (as taught by Baracchini et al.), because antisense of a short length are more easily synthesized and easier to deliver to cells than a vector expressing a full length antisense and because this length was the convention in the art. It would have been further obvious to make said antisense comprising modifications, including 2'-O-methoxyethyl, 5-methyl cytosine, chimeric oligonucleotides and modified internucleoside linkages, including phosphorothioate linkages, as taught by Baracchini et al., because such modifications were routine and well known in the art as modifications which enhance the stability, uptake and affinity of an antisense molecule (see for example Baracchini et al. column 6, paragraph 3) and such benefits would have been useful in a cell line inhibited in vitro for drug screening purposes. It would have been obvious to one of ordinary skill in the art to make a composition comprising said antisense and a pharmaceutically acceptable carrier, including a colloidal dispersion system, because pharmaceutically acceptable carriers, including colloidal dispersion systems (e.g. liposomes) were well known in the art for use with antisense molecules as a means to

deliver antisense molecules to cells *in vitro* (cell culture), as evidenced by Baracchini et al.

One skilled in the art would have been motivated to make an antisense molecule targeted to a nucleic acid encoding ribonuclease L because Silverman teach inhibiting the expression of ribonuclease L for antiviral drug screening and antisense was a well known means for inhibiting the expression of a target molecule *in vitro* and Maitra et al. teach that antisense to inhibit ribonuclease L in cell *in vitro*. One of ordinary skill in the art would be motivated to make such antisense of a length within the range of 8-50 nucleobases for ease of synthesis and delivery and because it is conventional in the art to make antisense within this range (as exemplified by Baracchini et al.). One of ordinary skill in the art would have been motivated to incorporate the modifications taught by Baracchini et al. for the benefits of stability and improved hybridization.

One skilled in the art would have expected to be able to find antisense which inhibits the expression of ribonuclease L because the sequence of nucleic acids encoding ribonuclease L, including SEQ ID NO:3 were known in the art (see for example Zhou et al.) and methods of screening for antisense to a known gene was routine (see for example Milner). One skilled in the art would have expected to be able to find compounds which inhibit the expression of ribonuclease L to varying degrees, even within the ranges of 60%, 80%, 90% or more, under some conditions, using routine optimization, changing the conditions of inhibition, changing antisense length and optimizing the modifications incorporated into the antisense, as discussed in the screening techniques in Baracchini et al.

It would have been obvious to one of ordinary skill in the art to use antisense targeted to a nucleic acid encoding ribonuclease L in a method of inhibiting the expression of ribonuclease L in cells *in vitro* (cell culture), because Maitra et al. teach using an expressed antisense targeted to ribonuclease L to inhibit the expression of ribonuclease L in cells *in vitro*, and it would be an obvious use for an antisense molecule designed to hybridize to and inhibit the expression of a nucleic acid encoding ribonuclease L.

Therefore, the invention of claims 1, 2, 4-15 and 21-23 would have been obvious to one of ordinary skill in the art, as a whole, at the time the instant invention was made.

Response to Arguments

Applicant's arguments filed September 4, 2003 have been fully considered but they are not persuasive. In response to the rejection of record of claims 1, 2 and 4-15 under 35 U.S.C. 103(a) as being unpatentable over Maitra et al. in view of Silverman et al., Zhou et al., Milner et al. and Barracchini et al. Applicant argues the references do not provide a motivation for the invention as a whole. Applicant argues that the Maitra reference does not teach using RNase L antisense that is less than the full length of the coding region, particularly in the specific range of 8 to 50 nucleotides, as claimed. Applicant argues that the Maitra reference makes no suggest to shorten their antisense to less than full length. This has not been found to be persuasive because the Maitra reference is not relied upon to teach compounds within the range of 8 to 50 nucleotides. Maitra et al. clearly teach the use of antisense to decrease the expression level of RNase L and the art within the field of antisense teaches compounds smaller than full

length, including compounds within the length of 8 to 50 nucleotides and taught the benefits of using compounds of this size, as exemplified by Baracchini et al. The skilled artisan would be motivated to use this length for the benefits discussed in the rejection of record and because it was the convention in the art.

Applicant argues that the Silverman reference does not cure the deficiencies of the Maitra reference because Silverman et al. does not teach compounds within this length, nor does it suggest inhibition of RNase L by antisense because it uses a totally unrelated gene disruption method. This is not persuasive because Silverman is not relied upon to teach antisense inhibition, but is relied upon to teach the desirability of decreasing the expression of RNase L for anti-viral drug screening in cells. The skilled artisan would recognize that expression of Rnase L could be reduced for this purpose using other art recognized methods, and it would be obvious to substitute the well known method of antisense.

Applicant argues that Zhou et al. does not overcome the deficiencies of the other references because they do not teach or suggest antisense and cloning the gene would not teach or suggest such. This is not found to be persuasive because Zhou et al. is not relied upon to teach antisense inhibition for the rejection of record. Zhou et al. teaches the sequence of the RNase L gene, this sequence would have provided the sequence by which the skilled artisan could design antisense, based on the teachings in the other references cited in the rejection of record.

Applicant argues that neither Milner et al. nor Baracchini et al. even mention RNase L, however, these references are not relied upon to teach RNase L but are relied

upon to support that methods of screening for antisense to a known gene and the modifications claimed were well known in the art at the time of the invention.

Applicant argues that the Office Action fails to provide a "motivating force" to combine the teachings of the cited references, because there is only a general teaching of a gene and antisense. Applicant argues Silverman is not motivating because it would motivate one to disrupt the gene to search for drugs that induce transcription of RNase L or activate RNase L, whereas antisense could only decrease RNase L expression and further that the skilled artisan would not be motivated to pick and choose the claimed elements from the many teachings in the cited references. This is not persuasive because the teaching provided by the art is more than a general teaching of a gene and antisense, but rather a specific teaching to use antisense to inhibit the expression of RNase L and a specific teaching of inhibiting the expression of RNase L in cells. The skilled artisan would have had specific motivation to modify the antisense targeted to RNase L previously taught in the art by making the length shorter and incorporating known modifications because such changes were well known and provided well known benefits applicable to the types of methods disclosed in the art. Although Silverman et al. discloses inhibition of RNase L expression using a gene disruption technique, the skilled artisan would recognize that the expression of RNase L could be performed using antisense, with the added advantage of being reversible, whereas gene disruption is not. Although Silverman is screening for drugs that activate RNase L or induce transcription of RNase L, the assay they teach requires the down regulation of RNase L

Art Unit: 1635

expression, which the skilled artisan would recognize as an application suitable for antisense.

Conclusion

THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen A. Lacourciere whose telephone number is (571) 272-0759. The examiner can normally be reached on Monday-Thursday 8:30-6:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader can be reached on (571) 272-0760. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 305-1935 for After Final communications.

Karen A. Lacourciere
KAREN A. LACOURCIERE, PH.D.
PRIMARY EXAMINER